论文部分内容阅读
目的探讨氟尿嘧啶缓释植入剂对巨块型宫颈癌患者的新辅助化疗疗效及安全性。方法收集2015年2月至2017年4月我院36例接受新辅助化疗的巨块型宫颈癌患者:17例行多西他赛+奈达铂(TP)+中人氟安方案新辅助化疗,19例行TP方案新辅助化疗。对比两组之间化疗有效率、术中情况、术后病理特征及不良反应的差异。结果观察组近期化疗有效率94.11%,高于对照组的63.16%,差异有统计学意义(P<0.05),术中情况、术后病理特征及不良反应与对照组无统计学差异(P>0.05)。结论氟尿嘧啶缓释植入剂对局部晚期宫颈癌具有较好的疗效,不增加手术并发症发生率和药物不良反应发生率。
Objective To investigate the efficacy and safety of fluorouracil sustained-release implantable neoadjuvant chemotherapy in patients with massive cervical cancer. Methods A total of 36 patients with massive cervical cancer receiving neoadjuvant chemotherapy from February 2015 to April 2017 in our hospital were enrolled in this study. Neonadjuvant chemotherapy was given in 17 patients treated with docetaxel plus nedaplatin (TP + , 19 cases of TP regimen neoadjuvant chemotherapy. Compare the two groups of chemotherapy efficiency, intraoperative conditions, postoperative pathological features and adverse reactions. Results The effective rate of chemotherapy in the observation group was 94.11%, higher than that of the control group (63.16%), the difference was statistically significant (P <0.05). The intraoperative status, postoperative pathological features and adverse reactions were not significantly different from those in the control group (P> 0.05). CONCLUSION: Fluorouracil sustained release implants have a good curative effect on locally advanced cervical cancer without increasing the incidence of surgical complications and the incidence of adverse drug reactions.